HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

P&G v. Amway

This article was originally published in The Rose Sheet

Executive Summary

Houston federal judge Vanessa Gilmore rules P&G's Lanham Act claim that multi-level marketer disparaged Crest toothpaste is barred by Salt Lake City federal judge's earlier decision denying P&G leave to add product disparagement claims in a parallel lawsuit against Amway. In a Jan. 8 opinion, Gilmore also finds remaining P&G claims alleging Amway circulated false rumors that P&G was associated with Satanism are similarly barred by res judicata effect of the Utah court's rulings, which were upheld by a Denver appeals court Jan. 6. P&G says it is "disappointed" in the rulings; Amway says court decisions end P&G's litigation against the company related to the Satanism rumors, with two cases still pending against Amway distributors...

You may also be interested in...



Coronavirus Update: After 'Warp Speed' Snub, Novavax Awarded US Military Vaccine Deal

Progress for two US-based companies in the race to develop a COVID-19 vaccine.

China Approves More Drugs For Cancer, Rare Diseases

BeiGene's BTK inhibitor for leukemia/lymphoma and Sanofi/Genzyme's enzyme replacement therapy for MPS I among novel drugs newly approved in China.

QUOTED. 5 June 2020. US FDA.

A new document from the US FDA details acceptable substitutions for COVID-19 testing components that may be difficult to come by. See what the regulatory agency said about it here.

UsernamePublicRestriction

Register

LL1132587

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel